

DMD # 76406

Short Communication

Role of CYP2B in Phenobarbital-induced Hepatocyte Proliferation in Mice

Lei Li, Xiaochen Bao, Qing-Yu Zhang, Masahiko Negishi, Xinxin Ding

College of Nanoscale Science, SUNY Polytechnic Institute, Albany, NY 12203 (LL, XD);

Wadsworth Center, New York State Department of Health, and School of Public Health,

University at Albany, Albany, NY 12201 (LL, XB, QZ, XD); National Institute of Environmental

Health Sciences, NIH, Research Triangle Park, NC 27709 (MN)

DMD # 76406

RUNNING TITLE: CYP2B and PB-induced hepatocyte proliferation

ADDRESS CORRESPONDENCE TO:

Dr. Xinxin Ding, College of Nanoscale Science, SUNY Polytechnic Institute, 257 Fuller Road,
NanoFab East, Albany, NY 12203; Tel. 518-956-7057; E-mail: xding@sunypoly.edu

Number of Text Pages:	11
Number of Tables:	1
Number of Figures:	2
Number of References:	44
Number of words	
Abstract:	243
Introduction:	616
Results and Discussion:	1184

ABBREVIATIONS: PB, phenobarbital; CAR, constitutive androstane receptor; PCR, polymerase chain reaction; WT, wild-type; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; BrdU, bromodeoxyuridine.

DMD # 76406

ABSTRACT

Phenobarbital (PB) promotes liver tumorigenesis in rodents, in part through activation of the constitutive androstane receptor (CAR) and the consequent changes in hepatic gene expression and increases in hepatocyte proliferation. A typical effect of CAR activation by PB is a marked induction of *Cyp2b10* expression in the liver; the latter has been suspected to be vital for PB-induced hepatocellular proliferation. This hypothesis was tested here, by using a *Cyp2a(4/5)bgs*-null (null) mouse model, in which all *Cyp2b* genes are deleted. Adult male and female wild-type (WT) and null mice were treated intraperitoneally with PB at 50 mg/kg, once daily for five successive days and tested on day 6. The liver-to-body weight ratio, an indicator of liver hypertrophy, was increased by 47% in male WT mice, but by only 22% in male *Cyp2a(4/5)bgs*-null mice, by the PB treatment. The fractions of bromodeoxyuridine-positive hepatocyte nuclei, assessed as a measure of the rate of hepatocyte proliferation, were also significantly lower in PB-treated male null mice, compared to PB-treated male WT mice. However, whereas few proliferating hepatocytes were detected in saline-treated mice, many proliferating hepatocytes were still detected in PB-treated male null mice. In contrast, female WT mice were much less sensitive than male WT mice to PB-induced hepatocyte proliferation, and PB-treated female WT and PB-treated female null mice did not show significant difference in rates of hepatocyte proliferation. These results indicate that CYP2B induction plays a significant, but partial, role in PB-induced hepatocyte proliferation in male mice.

DMD # 76406

INTRODUCTION

Many studies have shown that phenobarbital (PB) and related compounds can promote liver tumorigenesis in rodents (Whysner et al., 1996; IARC, 2001). In mode-of-action evaluations of PB-induced rodent liver tumor formation, the key event was considered to be activation of the constitutive androstane receptor (CAR) (Yamamoto et al., 2004), which leads to a multitude of downstream events, including altered expression of CAR target genes and cellular signaling, increased cell proliferation, and the development of pathological changes, in the liver (Elcombe et al., 2014). Some of the PB-activated CAR target genes, such as *Mmd2*, *Foxm1b*, and *Cyclins*, have been suggested to be important in PB-induced liver hyperplasia and the subsequent development of liver tumors (Ledda-Columbano et al., 2002; Huang et al., 2005; Blanco-Bose et al., 2008); but the molecular mechanism of the CAR-mediated activation of hepatocyte proliferation is still not fully understood.

A number of cytochrome P450 genes, particularly the *Cyp2b* genes, are among the most highly induced hepatic CAR target genes; hepatic induction of *Cyp2b* is a characteristic downstream event of CAR activation by PB (Honkakoski et al., 1998). However, it is unknown whether the induction of *Cyp2b* is necessary for CAR-mediated activation of hepatocyte proliferation and tumorigenesis. There has been no study that directly examined the possible role of CYP2B enzymes in PB-induced hepatocyte proliferation.

The CYP2B enzymes metabolize many drugs, such as cyclophosphamide, ifosfamide, bupropion, nicotine, and propofol, and a large number of environmental chemicals, such as aflatoxin B1, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, and chlorpyrifos (Dicke et al., 2005; Wang and Tompkins, 2008; Turpeinen and Zanger, 2012). Humans have a single *CYP2B* gene, *CYP2B6*; whereas mice have five *Cyp2b* genes, *Cyp2b9*, *Cyp2b10*, *Cyp2b13*, *Cyp2b19*, and *Cyp2b23* (Nelson et al., 2004). In mice, *Cyp2b9*, *Cyp2b10*, and *Cyp2b13* are the forms

DMD # 76406

primarily expressed in the liver (Finger et al., 2011). *Cyp2b10* is transcriptionally regulated by CAR (Honkakoski et al., 1998; Zhang et al., 2002; Wang et al., 2003; Kretschmer and Baldwin, 2005), and it is highly inducible by PB treatment (Honkakoski et al., 1998; Li-Masters and Morgan, 2001). *Cyp2b9* and *Cyp2b13* are female predominant in most mouse strains (Damiri et al., 2012). There was conflicting evidence as to whether *Cyp2b9* is inducible by PB (Rivera-Rivera et al., 2003); but *Cyp2b13* has been shown to be inducible by PB (Stupans et al., 1984).

We have recently reported the generation and characterization of a *Cyp2a(4/5)bgs*-null mouse model, in which *Cyp2a4*, *Cyp2a5*, all five *Cyp2b* genes, *Cyp2g1*, and *Cyp2s1* are deleted (Li et al., 2013; Wei et al., 2013). Among the deleted genes, only *Cyp2a4/5* and *Cyp2b9/10/13* are expressed in liver, and *Cyp2a4* and *Cyp2b9/13* are female predominant (Damiri et al., 2012; Li et al., 2013). The deletion of the gene cluster did not lead to any notable developmental or morphological changes, and there was no significant compensatory change in the expression of CPR or various other major P450 enzymes, including CYP2C, CYP3A, CYP2E1, and CYP1A1/2 (Wei et al., 2013). A report of a *Cyp2b*-knockdown mouse also showed absence of any notable biological phenotypes (Damiri et al., 2012). The *Cyp2a(4/5)bgs*-null mouse, in which an induction of the *Cyp2b* genes would not occur upon PB treatment, was utilized in the present study to test the hypothesis that *Cyp2b* induction is mechanistically important for PB-induced hepatocyte proliferation. We first confirmed that *Cyp2b10* is induced by PB in WT mice but not in *Cyp2a(4/5)bgs*-null mice, and that the *Cyp2a(4/5)bgs* gene deletion did not change the inducibility of other *Cyp* genes in the liver. We then assessed the PB-induced hepatic hypertrophy (weight increase) and hyperplasia [bromodeoxyuridine (BrdU) incorporation] in *Cyp2a(4/5)bgs*-null and wild-type (WT) mice (both male and female). Our results indicate that CYP2B plays a significant, but partial, role in PB-induced hepatocyte proliferation in male mice.

DMD # 76406

MATERIALS AND METHODS

Animals and Treatments. All studies with mice were approved by the Institutional Animal Care and Use Committee of the Wadsworth Center. WT mice and *Cyp2a(4/5)bgs*-null mice, male and female, all on C57BL/6 background, were allowed free access to water and food. To induce hepatocyte proliferation, 2-3-month old mice were treated with five consecutive daily injections (i.p.) of phenobarbital sodium (Sigma-Aldrich, St. Louis, MO; 50 mg/kg/day, in saline) or saline alone. Mice were weighed and then euthanized by CO₂ overdose at 24 h after the last injection. The whole liver was removed carefully and weighed. A portion of liver tissue was stored at 10% formalin for histological analysis and the remainder was stored at -80 °C until use.

RNA-PCR Analysis. Total RNA was prepared using Trizol reagent (ThermoFisher, Waltham, MA) and stored at -80 °C. Reverse transcription of RNA was carried out using the SuperScript III first-strand synthesis system (ThermoFisher), with use of 5 µg of total RNA, pretreated with DNase I (ThermoFisher) at room temperature for 15 min, and 0.5 µg of oligo(dT), in a final volume of 20 µl. Realtime PCR was performed on an ABI StepOne Plus PCR system (Applied Biosystems, Foster City, CA), using SYBR Green PCR core reagent (Applied Biosystem), essentially as described previously (Zhang et al., 2007). Reactions were performed, in duplicate, in a total volume of 10 µl, with 2 µl of diluted (1:15) first-strand cDNA as template. Reactions were initiated at 50 °C for 2 min (to allow degradation of any potential contaminating PCR products by the AmpErase UNG), followed by denaturation at 95 °C for 10 min, and then 45 cycles of amplifications (95 °C for 15 s, 62 °C for 1 min). The final melting curve analysis was carried out at 95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s. The following primers were used: GAPDH, forward 5'-tgtgaacggattggccgta-3' and reverse 5'-tcgctcctggaagatggtga-3' (Wei et al., 2012); CYP3A11, forward 5'-ggatgagatcgatgaggctctg-3' and reverse: 5'-

DMD # 76406

caggtattccatctccatcacagt-3'; CYP2B10, forward 5'-caggtgatcggtcacacc-3' and reverse: 5'-tgactgcatctgagtatggcatt-3' (Pan et al., 2000); CYP2A5, forward 5'-TCTGTTGCTCATGAAGTACC-3' and reverse 5'-TTGTCATCTAGGAAGTGCTT-3'; and CYP2C29, forward 5'-GGGCTCAAAGCCTACTGTCA-3' and reverse 5'-AACGCCAAAACCTTTAA-3' (Zhang et al., 2003).

Histology and BrdU Assay. Mice were injected intraperitoneally with BrdU (Sigma-Aldrich), once, at 100 mg/kg body weight, at 90 min before the first saline or PB treatment, and they were also maintained on BrdU-containing drinking water (0.8 mg/mL) for the duration of the experiment, to achieve continuous labeling (Blanco-Bose et al., 2008). Liver tissues were fixed in 10% neutral buffered formalin, and then sectioned at 4 μ m for hematoxylin-eosin staining or BrdU immunostaining. BrdU assay was performed as described previously (Moser et al., 2009). Briefly, the sections were deparaffinized, soaked in H₂O₂ for blocking endogenous peroxidase, and subjected to heat-induced epitope retrieval. Subsequently, the sections were stained with mouse anti-BrdU (1:500; Abcam, Cambridge, MA) and the slides were counterstained with hematoxylin, dehydrated, and cover-slipped. The numbers of BrdU-positive and BrdU-negative hepatocyte nuclei were tallied microscopically using ten randomly selected sections, three section per animal (at least 1,000 hepatocyte nuclei), at \times 200 magnification. The threshold for identification of BrdU-positive nuclei was set empirically, and the independent results from two experienced researchers were averaged to produce the final data.

Data Analysis. Statistical significance of differences among groups in various parameters was examined with 2-way analysis of variance (ANOVA), followed by Bonferroni or Sidak's multiple comparisons posttest, using GraphPad Prism.

DMD # 76406

RESULTS AND DISCUSSION

To confirm the induction of *Cyp2b10* by PB in WT mice and the lack thereof in the null mice, we compared CYP2B10 mRNA levels in the livers of saline- or PB-treated WT and *Cyp2a(4/5)bgs*-null mice. The levels of CYP2A5, CYP2C29, and CYP3A11 mRNAs were also determined, as controls. As shown in Figure 1, at 24 h following five consecutive daily injection of PB (50 mg/kg/day, i.p.), CYP2B10 mRNA levels were remarkably increased in WT mice, compared to the saline-treated control group. In contrast, CYP2B10 mRNA could not be detected in the *Cyp2a(4/5)bgs*-null mice, in either saline or PB group, which confirms the gene deletion. As a control, the levels of CYP3A11 and CYP2C29 mRNA were also increased by the PB treatment, as reported previously (Zhang et al., 2003), in both WT and the *Cyp2a(4/5)bgs*-null mice, thus confirming PB-mediated activation of CAR in the *Cyp2a(4/5)bgs*-null mice. CYP2A5 mRNA was not induced by PB in WT mice and it was not detected in the *Cyp2a(4/5)bgs*-null mice. These findings were consistent in males and females, except for a lower extent of CYP2B10 induction in WT female mice (Fig. 1A). Taken together, these results confirm that PB is a CYP2B10 inducer but not CYP2A5 inducer, and that the deletion of *Cyp2a(4/5)bgs* genes did not affect the regulation of other major CYPs (CYP3A and CYP2C) by PB. Thus, the *Cyp2a(4/5)bgs*-null mouse is useful for subsequent studies on the role of CYP2B in PB-induced hepatocyte proliferation in the WT mice.

Phenobarbital treatment is known to induce hepatocyte proliferation in male mice, an event that could further develop into hepatocellular carcinogenesis (Blanck et al., 1986; El-Serag and Rudolph, 2007). Both hypertrophy and hyperplasia occur during hepatocyte proliferation. To examine the role of CYP2B in PB-induced hepatic hypertrophy, we measured the liver weight and liver-to-bodyweight ratio in WT and *Cyp2a(4/5)bgs*-null mice, both male and female, after

DMD # 76406

PB or saline treatment. As shown in Table 1, the liver weights were greater in PB-treated groups than in saline-treated groups, for both WT and *Cyp2a(4/5)bgs*-null mice, male or female. The liver-to-bodyweight ratios were also significantly higher in PB-treated male WT (by ~47%), but not in PB-treated male or female *Cyp2a(4/5)bgs*-null, or PB-treated female WT mice, relative to the corresponding saline-treated mice. The liver-to-bodyweight ratio was also significantly greater in PB-treated male WT than in PB-treated male *Cyp2a(4/5)bgs*-null mice ($p < 0.01$), which indicated that the PB-induced hepatic hypertrophy in male mice was partially dependent on the presence of the *Cyp2a(4/5)bgs* genes.

To examine the role of CYP2B in PB-induced hepatic hyperplasia, we examined hepatic BrdU incorporation in WT and *Cyp2a(4/5)bgs*-null mice treated concomitantly with BrdU and PB for five consecutive days. As shown in Figures 2A and 2B, the numbers of BrdU-positive hepatocytes were considerably greater in the livers of PB-treated WT and *Cyp2a(4/5)bgs*-null mice, male or female, than in the corresponding saline-treated groups; the latter had very few BrdU-positive cells. Among the PB-treated groups, the abundance of BrdU-positive cells was significantly greater in male WT mice than in male *Cyp2a(4/5)bgs*-null mice, which indicates that the PB-induced increase in BrdU incorporation in WT male mice was partly dependent on the presence of the *Cyp2a(4/5)bgs* genes. Consistent with the sex difference in PB-induced hepatic hypertrophy, female mice also showed a lower response to PB-induced hyperplasia than male mice did, and the abundance of BrdU-positive hepatocytes in females was not different between WT and *Cyp2a(4/5)bgs*-null mice.

Taken together, these results indicate that the *Cyp2a(4/5)bgs* genes play a significant, though partial, role in PB-induced hepatocyte proliferation in male mice. Given that the *Cyp2b* genes are the only ones induced by PB among the genes deleted in the *Cyp2a(4/5)bgs*-null mice,

DMD # 76406

our results support the hypothesis that induction of CYP2B is important for PB-induced hepatocyte proliferation. Of the *Cyp2b* genes, while *Cyp2b9*, *2b10* and *2b13* are all expressed in the liver, *Cyp2b9* and *2b13* are female predominant (Damiri et al., 2012; Li et al., 2013), and *Cyp2b10* is the most highly induced by PB (Li-Masters and Morgan, 2001). Thus, it can be deduced that *Cyp2b10* was involved in PB-induced hepatocyte proliferation in male mice. Notably, the association of hepatocyte proliferation with CYP2B induction has also been observed for other CYP2B inducers, such as the environmental pollutant potassium perfluorooctanesulfonate and the synthetic pyrethroid metofluthrin (Deguchi et al., 2009; Elcombe et al., 2012). It remains to be determined whether CYP2B induction contributes to the hepatic hypertrophy induced by these other compounds.

The mechanistic basis for the sex difference in the extent of PB-induced hepatocyte proliferation, and the apparent noninvolvement of CYP2B in the proliferative response in females, is currently not understood, but they may be partly explained by the lower extent of hepatic CYP2B induction by PB in females than in males. In that regard, our present result was consistent with previous reports, that PB induced CYP2B10 to a larger extent in males than in females (Li-Masters and Morgan, 2001; Stamou et al., 2014), and that male mice were more susceptible to PB-induced hepatocarcinogenesis than female mice (Heindryckx et al., 2009; Maronpot, 2009). This sex difference in CYP2B inducibility by PB does not appear to be due to a difference in CAR expression, as cytosolic (Hernandez et al., 2009) or nuclear (Saito et al., 2013) CAR protein level was found to be similar between untreated male and female mice. There was also no sex difference in nuclear CAR protein level after PB treatment (Saito et al., 2013). Our finding, that the PB-inducibility of two CAR target genes, *Cyp3a11* and *Cyp2c29*, was similar in male and female WT mice, and it was not altered in the *Cyp2a(4/5)bgs*-null mice,

DMD # 76406

further confirmed the absence of a sex difference in hepatic CAR activation, and the notion that CAR activity was not changed by the loss of the *Cyp2b* genes. The latter finding was consistent with results from a *Cyp2b*-knockdown mouse (Damiri et al., 2012).

The mechanistic link between CYP2B induction and hepatocyte proliferation remains to be determined. In one possible scenario, the large induction of CYP2B may promote hepatocyte proliferation through induction of reactive oxygen species (ROS) and increased oxidative stress (Imaoka et al., 2004; Dostalek et al., 2007; Dostalek et al., 2008). ROS and oxidative stress can activate various signaling pathways, including mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways, to promote hepatocyte proliferation (Galli et al., 2005; Dragin et al., 2006). Other studies have shown possible roles of β -catenin and the two-pore K^+ channel *Kcnk1* in the sex difference in PB-induced the hepatocyte proliferation (Braeuning et al., 2011; Saito et al., 2013). PB is not a preferred substrate for CYP2B (Pacifci, 2016), although the clearance of another barbiturate, pentobarbital, in mice appeared to involve enzymes encoded by the *Cyp2a(4/5)bgs* gene cluster (Wei et al., 2013). It is unclear whether the loss of the *Cyp2abgs* genes would cause a change in PB metabolism, but there has been no report demonstrating a role for PB metabolites in stimulating hepatocyte proliferation.

In summary, we confirmed that PB induces hepatic *Cyp2b10* expression and hepatocyte proliferation to greater extents in male mice than in female mice. In male mice, CYP2B plays a significant, but partial, role in PB-induced hepatocyte proliferation.

DMD # 76406

Acknowledgments

We gratefully acknowledge the use of the services of the Pathology Core and the Advanced Light Microscopy and Image Analysis Core Facilities of the Wadsworth Center. We thank Ms. Weizhu Yang for assistance with mouse breeding.

Authorship Contributions

Participated in research design: LL, QZ, MN, XD

Conducted experiments: LL, XB

Performed data analysis: LL, XB, XD

Wrote or contributed to the writing of the manuscript: LL, XB, QZ, MN, XD

REFERENCES

- Blanck A, Hansson T, Gustafsson JA, and Eriksson LC (1986) Pituitary grafts modify sex differences in liver tumor formation in the rat following initiation with diethylnitrosamine and different promotion regimens. *Carcinogenesis* **7**:981-985.
- Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, Moore DD, and Trump A (2008) C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. *Hepatology* **48**:1302-1311.
- Braeuning A, Heubach Y, Knorpp T, Kowalik MA, Templin M, Columbano A, and Schwarz M (2011) Gender-specific interplay of signaling through beta-catenin and CAR in the regulation of xenobiotic-induced hepatocyte proliferation. *Toxicol Sci* **123**:113-122.
- Damiri B, Holle E, Yu X, and Baldwin WS (2012) Lentiviral-mediated RNAi knockdown yields a novel mouse model for studying Cyp2b function. *Toxicol Sci* **125**:368-381.
- Deguchi Y, Yamada T, Hirose Y, Nagahori H, Kushida M, Sumida K, Sukata T, Tomigahara Y, Nishioka K, Uwagawa S, Kawamura S, and Okuno Y (2009) Mode of action analysis for the synthetic pyrethroid metofluthrin-induced rat liver tumors: evidence for hepatic CYP2B induction and hepatocyte proliferation. *Toxicol Sci* **108**:69-80.
- Dicke KE, Skrlin SM, and Murphy SE (2005) Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. *Drug Metab Dispos* **33**:1760-1764.
- Dostalek M, Brooks JD, Hardy KD, Milne GL, Moore MM, Sharma S, Morrow JD, and Guengerich FP (2007) In vivo oxidative damage in rats is associated with barbiturate response but not other cytochrome P450 inducers. *Mol Pharmacol* **72**:1419-1424.
- Dostalek M, Hardy KD, Milne GL, Morrow JD, Chen C, Gonzalez FJ, Gu J, Ding X, Johnson DA, Johnson JA, Martin MV, and Guengerich FP (2008) Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems. *J Biol Chem* **283**:17147-17157.
- Dragin N, Smani M, Arnaud-Dabernat S, Dubost C, Moranvillier I, Costet P, Daniel JY, and Peuchant E (2006) Acute oxidative stress is associated with cell proliferation in the mouse liver. *FEBS Lett* **580**:3845-3852.
- El-Serag HB and Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* **132**:2557-2576.
- Elcombe CR, Elcombe BM, Foster JR, Chang SC, Ehresman DJ, and Butenhoff JL (2012) Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARalpha and CAR/PXR. *Toxicology* **293**:16-29.
- Elcombe CR, Peffer RC, Wolf DC, Bailey J, Bars R, Bell D, Cattley RC, Ferguson SS, Geter D, Goetz A, Goodman JI, Hester S, Jacobs A, Omiecinski CJ, Schoeny R, Xie W, and Lake BG (2014) Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. *Crit Rev Toxicol* **44**:64-82.
- Finger JH, Smith CM, Hayamizu TF, McCright IJ, Eppig JT, Kadin JA, Richardson JE, and Ringwald M (2011) The mouse Gene Expression Database (GXD): 2011 update. *Nucleic Acids Res* **39**:D835-841.

DMD # 76406

- Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, Tarocchi M, Grappone C, Pellegrini G, Benedetti A, Surrenti C, and Casini A (2005) Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. *Hepatology* **41**:1074-1084.
- Heindryckx F, Colle I, and Van Vlierberghe H (2009) Experimental mouse models for hepatocellular carcinoma research. *Int J Exp Pathol* **90**:367-386.
- Hernandez JP, Mota LC, Huang W, Moore DD, and Baldwin WS (2009) Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). *Toxicology* **256**:53-64.
- Honkakoski P, Zelko I, Sueyoshi T, and Negishi M (1998) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. *Mol Cell Biol* **18**:5652-5658.
- Huang W, Zhang J, Washington M, Liu J, Parant JM, Lozano G, and Moore DD (2005) Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. *Mol Endocrinol* **19**:1646-1653.
- IARC (2001) Some thyrotropic agents. *IARC Monogr Eval Carcinog Risks Hum* **79**:i-iv, 1-725.
- Imaoka S, Osada M, Minamiyama Y, Yukimura T, Toyokuni S, Takemura S, Hiroi T, and Funae Y (2004) Role of phenobarbital-inducible cytochrome P450s as a source of active oxygen species in DNA-oxidation. *Cancer Lett* **203**:117-125.
- Kretschmer XC and Baldwin WS (2005) CAR and PXR: xenosensors of endocrine disrupters? *Chem Biol Interact* **155**:111-128.
- Ledda-Columbano GM, Pibiri M, Concas D, Cossu C, Tripodi M, and Columbano A (2002) Loss of cyclin D1 does not inhibit the proliferative response of mouse liver to mitogenic stimuli. *Hepatology* **36**:1098-1105.
- Li-Masters T and Morgan ET (2001) Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. *Drug Metab Dispos* **29**:252-257.
- Li L, Jia K, Zhou X, McCallum SE, Hough LB, and Ding X (2013) Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse. *J Pharmacol Exp Ther* **347**:746-754.
- Maronpot RR (2009) Biological Basis of Differential Susceptibility to Hepatocarcinogenesis among Mouse Strains. *J Toxicol Pathol* **22**:11-33.
- Moser GJ, Foley J, Burnett M, Goldsworthy TL, and Maronpot R (2009) Furan-induced dose-response relationships for liver cytotoxicity, cell proliferation, and tumorigenicity (furan-induced liver tumorigenicity). *Exp Toxicol Pathol* **61**:101-111.
- Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. *Pharmacogenetics* **14**:1-18.
- Pacifici GM (2016) Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. *Curr Pediatr Rev* **12**:48-54.
- Pan J, Xiang Q, and Ball S (2000) Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver. *Drug Metab Dispos* **28**:709-713.
- Rivera-Rivera I, Kim J, and Kemper B (2003) Transcriptional analysis in vivo of the hepatic genes, Cyp2b9 and Cyp2b10, by intravenous administration of plasmid DNA in mice. *Biochim Biophys Acta* **1619**:254-262.

DMD # 76406

- Saito K, Moore R, and Negishi M (2013) Nuclear receptor CAR specifically activates the two-pore K⁺ channel *Kenk1* gene in male mouse livers, which attenuates phenobarbital-induced hepatic hyperplasia. *Toxicol Sci* **132**:151-161.
- Stamou M, Wu X, Kania-Korwel I, Lehmler HJ, and Lein PJ (2014) Cytochrome p450 mRNA expression in the rodent brain: species-, sex-, and region-dependent differences. *Drug Metab Dispos* **42**:239-244.
- Stupans I, Ikeda T, Kessler DJ, and Nebert DW (1984) Characterization of a cDNA clone for mouse phenobarbital-inducible cytochrome P-450b. *DNA* **3**:129-137.
- Turpeinen M and Zanger UM (2012) Cytochrome P450 2B6: function, genetics, and clinical relevance. *Drug Metabol Drug Interact* **27**:185-197.
- Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, and LeCluyse EL (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. *J Biol Chem* **278**:14146-14152.
- Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. *Curr Drug Metab* **9**:598-610.
- Wei Y, Li L, Zhou X, Zhang QY, Dunbar A, Liu F, Kluetzman K, Yang W, and Ding X (2013) Generation and characterization of a novel Cyp2a(4/5)bgs-null mouse model. *Drug Metab Dispos* **41**:132-140.
- Wei Y, Wu H, Li L, Liu Z, Zhou X, Zhang QY, Weng Y, D'Agostino J, Ling G, Zhang X, Kluetzman K, Yao Y, and Ding X (2012) Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model. *Drug Metab Dispos* **40**:1144-1150.
- Whysner J, Ross PM, and Williams GM (1996) Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. *Pharmacol Ther* **71**:153-191.
- Yamamoto Y, Moore R, Goldsworthy TL, Negishi M, and Maronpot RR (2004) The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. *Cancer Res* **64**:7197-7200.
- Zhang J, Huang W, Chua SS, Wei P, and Moore DD (2002) Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. *Science* **298**:422-424.
- Zhang QY, Dunbar D, and Kaminsky LS (2003) Characterization of mouse small intestinal cytochrome P450 expression. *Drug Metab Dispos* **31**:1346-1351.
- Zhang X, D'Agostino J, Wu H, Zhang QY, von Weymarn L, Murphy SE, and Ding X (2007) CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *J Pharmacol Exp Ther* **323**:570-578.

DMD # 76406

Footnotes

This work was supported in part by the National Institutes of Health [Grants CA092596, ES020867, and GM082978], and in part by the Intramural Research Program of the National Institutes of Health [National Institute of Environmental Health Sciences].

Parts of this work were previously presented as a poster at the Society of Toxicology 54th Annual Meeting in San Diego, CA, March 22–26, 2015.

Address correspondence to:

Dr. Xinxin Ding, College of Nanoscale Science, SUNY Polytechnic Institute, 257 Fuller Road, Albany, NY 12203; E-mail: xding@sunypoly.edu

DMD # 76406

Legends to Figures

Figure 1. Effects of PB on hepatic CYP2A5, CYP2B10, CYP2C29, and CYP3A11 mRNA expression. Male and female WT and *Cyp2a(4/5)bgs*-null mice (2-3-month old) were treated with PB (50 mg/kg/day, i.p.) or saline, once daily for five consecutive days. Livers from individual mice were obtained 24 h after the last dose, for RNA isolation and PCR analysis. Data represent means \pm S.D. (n=3-4), and were normalized by the levels of GAPDH. *, $p < 0.05$; **, $p < 0.01$ (2-way ANOVA with Bonferroni posttest).

Figure 2. Effects of PB on hepatic hyperplasia. A, immunohistochemical staining of BrdU-positive cells (brown color; arrow) in paraffin sections of livers from WT and *Cyp2a(4/5)bgs*-null mice after five days of treatment with PB or saline, as described in *Materials and Methods*. Typical results are shown. B, relative abundance of BrdU-positive nuclei among nuclei of all hepatocytes. The percentage of BrdU-positive nuclei in hepatocytes was compared among various groups (male or female, PB or saline, WT or *Cyp2a(4/5)bgs*-null). Data represent means \pm S.D. (n=3-4). **, $p < 0.01$ (2-way ANOVA with Bonferroni posttest).

DMD # 76406

TABLE 1

Effects of PB on hepatic hypertrophy in WT and Cyp2a(4/5)bgs-null mice

Liver weight and liver-to-bodyweight ratio were determined for 2-3 month old WT and *Cyp2a(4/5)bgs*-null mice after PB or saline treatment. Data represent means \pm S.D. (n=3-4).

Sex	Strain	Liver weight (g)			Liver-to-bodyweight ratio		
		Saline	PB	(PB-Saline)/Saline	Saline	PB	(PB-Saline)/Saline
Male	WT	1.47 \pm 0.15	2.54 \pm 0.27 ^a	73%	0.048 \pm 0.006	0.069 \pm 0.004 ^a	47%
	Null	1.25 \pm 0.08	1.69 \pm 0.25 ^{b,c}	35%	0.046 \pm 0.004	0.056 \pm 0.002 ^c	22%
Female	WT	1.04 \pm 0.22	1.43 \pm 0.13 ^d	38%	0.045 \pm 0.005	0.051 \pm 0.004 ^d	13%
	Null	1.13 \pm 0.07	1.39 \pm 0.08	23%	0.046 \pm 0.003	0.049 \pm 0.003	6.5%

^a $p < 0.01$, compared to corresponding saline group (2-way ANOVA with Sidak's multiple comparisons posttest).

^b $p < 0.05$, compared to corresponding saline group.

^c $p < 0.01$, compared to corresponding WT group.

^d $p < 0.01$, compared to corresponding male group.

Fig. 1




Fig. 2

